4 November 2021 - NICE has published draft guidance which recommends a rebranded form of the drug mexiletine (Namuscla), for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.

It is estimated that around 250 people will be eligible to have Namuscla.

NICE has been asked to appraise Namuscla, as it is the only product for treating this condition with a UK marketing authorisation.

Read Pharma Times article